<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments for Drug Development Consultant and Regulatory Consultant</title>
	<atom:link href="http://www.damienbove.com/comments/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.damienbove.com</link>
	<description>Damien Bove Shares The Expertise</description>
	<lastBuildDate>Mon, 08 Mar 2010 07:51:02 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>Comment on ICH M3 (R2) Non-clinical Safety Studies Guidance updated by EMEA by admin</title>
		<link>http://www.damienbove.com/2009/07/28/ich-m3-r2-non-clinical-safety-studies-guidance-updated-by-emea/comment-page-1/#comment-7410</link>
		<dc:creator>admin</dc:creator>
		<pubDate>Mon, 08 Mar 2010 07:51:02 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?p=503#comment-7410</guid>
		<description>Hello, 

In most cases I would be confident that you can make an argument quickly and easily that a local tolerance test is not going to be required in this situation, however without knowing the details of the particular product I never say never, but it would be difficult to see a case why you would need it. 
Regards

Damien</description>
		<content:encoded><![CDATA[<p>Hello, </p>
<p>In most cases I would be confident that you can make an argument quickly and easily that a local tolerance test is not going to be required in this situation, however without knowing the details of the particular product I never say never, but it would be difficult to see a case why you would need it.<br />
Regards</p>
<p>Damien</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE-Marked Medical Devices - Cardiac Ablation Catheters. &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-7356</link>
		<dc:creator>Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE-Marked Medical Devices - Cardiac Ablation Catheters. &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Sat, 06 Mar 2010 11:30:29 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-7356</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on ICH M3 (R2) Non-clinical Safety Studies Guidance updated by EMEA by Local Tolerance studies needed for oral formulations and Intrmuscular injectables</title>
		<link>http://www.damienbove.com/2009/07/28/ich-m3-r2-non-clinical-safety-studies-guidance-updated-by-emea/comment-page-1/#comment-7308</link>
		<dc:creator>Local Tolerance studies needed for oral formulations and Intrmuscular injectables</dc:creator>
		<pubDate>Fri, 05 Mar 2010 05:36:46 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?p=503#comment-7308</guid>
		<description>Dear Sir/ Mam


Plz let me know whether local tolerance studies is needed for oral formulations (Generic) also.</description>
		<content:encoded><![CDATA[<p>Dear Sir/ Mam</p>
<p>Plz let me know whether local tolerance studies is needed for oral formulations (Generic) also.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by Drug Regulators, FDA, Publish Draft Guidance on Adaptive Design Clinical Trials for Drugs and Biologicals. &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-7283</link>
		<dc:creator>Drug Regulators, FDA, Publish Draft Guidance on Adaptive Design Clinical Trials for Drugs and Biologicals. &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Thu, 04 Mar 2010 10:23:54 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-7283</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Pharma &#8211; Biotech Intellectual Property &amp; CMC Services by Drug Regulators, FDA, Publish Guidance on Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/drug-development-and-planning-services/pharma-biotech-intellectual-property-cmc-services/comment-page-1/#comment-7232</link>
		<dc:creator>Drug Regulators, FDA, Publish Guidance on Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Wed, 03 Mar 2010 10:20:44 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=623#comment-7232</guid>
		<description>[...] CMC Consultancy Services [...]</description>
		<content:encoded><![CDATA[<p>[...] CMC Consultancy Services [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by Drug Regulators, FDA, Publish Draft Guidance for Industry, Non-Inferiority Clinical Trials &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-7182</link>
		<dc:creator>Drug Regulators, FDA, Publish Draft Guidance for Industry, Non-Inferiority Clinical Trials &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Tue, 02 Mar 2010 10:14:49 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-7182</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by Drug Regulators, EMEA (EMA), Publish Draft Guidance on the Investigation of Bioequivalence. &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-7145</link>
		<dc:creator>Drug Regulators, EMEA (EMA), Publish Draft Guidance on the Investigation of Bioequivalence. &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Mon, 01 Mar 2010 10:49:28 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-7145</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by Drug Regulators, MHRA, Publish Consultation Document on ARM 65 Algopain-EZE 140MG Medicated Plaster, Request to Reclassify a Prodcut from POM to P &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-7060</link>
		<dc:creator>Drug Regulators, MHRA, Publish Consultation Document on ARM 65 Algopain-EZE 140MG Medicated Plaster, Request to Reclassify a Prodcut from POM to P &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Sat, 27 Feb 2010 10:43:46 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-7060</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by Drug Regulators, EMA (EMEA), Publish draft guidance on Clinical Investigations in the Treatment of Diabetes Mellitus &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-7014</link>
		<dc:creator>Drug Regulators, EMA (EMEA), Publish draft guidance on Clinical Investigations in the Treatment of Diabetes Mellitus &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Fri, 26 Feb 2010 10:41:31 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-7014</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on How to Write a Business Plan by regulators EMEA (EMA), Publish a Concept Paper on the Need For Guidance on Clinical Investigations of Medicinal Products in the Treatment of Diabetes Mellitus &#124; Drug Development Consultant and Regulatory Consultant</title>
		<link>http://www.damienbove.com/how-to-write-a-business-plan/comment-page-3/#comment-6982</link>
		<dc:creator>regulators EMEA (EMA), Publish a Concept Paper on the Need For Guidance on Clinical Investigations of Medicinal Products in the Treatment of Diabetes Mellitus &#124; Drug Development Consultant and Regulatory Consultant</dc:creator>
		<pubDate>Thu, 25 Feb 2010 10:33:27 +0000</pubDate>
		<guid isPermaLink="false">http://www.damienbove.com/?page_id=632#comment-6982</guid>
		<description>[...] How to Write a Business Plan [...]</description>
		<content:encoded><![CDATA[<p>[...] How to Write a Business Plan [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
